Kalshi Drug Trial Markets: Your Trial Team Is Now a CFTC Risk

Kalshi Now Lists Bets on Drug Trials and FDA Decisions

Kalshi lets verified traders take positions on whether late-stage clinical trials succeed and whether the FDA approves specific drugs. On July 16, 2026, Kalshi announced a pilot suite of prediction markets on clinical trial outcomes and FDA regulatory decisions, run with AppliedXL, which provides the resolution infrastructure. Law360 reports that the launch has raised insider-trading and trial-integrity concerns across the industry.

But here is the part the headlines are missing. The debate has focused on whether Kalshi can police its own market. The sharper exposure sits with the drugmaker. Kalshi's safeguards work by naming who inside a trial cannot trade, which turns every sponsor's trial roster into a map of the people whose trading regulators will scrutinize.

Here is what happened, why it matters, and what your leadership team should decide this quarter.

What Kalshi Built, and Who It Shut Out

Kalshi says the pilot is limited to late-stage trials, lists a contract only after the trial finishes enrolling, and requires employment verification for all traders in these markets. Listing only after enrollment closes addresses recruitment manipulation. The late-stage limit and employment verification target insider risk, and Kalshi says its existing prohibition on trading by anyone holding material nonpublic information applies in full. On top of that, Kalshi relies on exclusion. According to the Boston Globe, Kalshi said it would bar trading by:

• Employees of the drugmaker running the trial
• People with visibility into unblinded data, such as lead investigators, lead biostatisticians and safety-monitoring committee members
• Trial participants

The Globe's account does not say whether contract research organizations, site coordinators, data vendors or family members are covered. A sponsor should not assume Kalshi's exclusions reach everyone who touches trial data.

Reading the Enforcement Signal: The CFTC Has Already Fired

Prediction market insider trading is not a theoretical risk. On February 25, 2026, the CFTC Division of Enforcement issued a prediction markets advisory (Release No. 9185-26) following two Kalshi insider-trading and fraud cases. It said the Commission has full authority to police illegal trading on any designated contract market, including prediction markets.

The agency then acted. According to a Lowenstein Sandler alert, in April 2026 the CFTC brought what was described as its first insider-trading charge involving event contracts, and federal prosecutors in Manhattan unsealed a parallel criminal indictment the same day. The message is unmistakable: regulators and prosecutors are treating insider trading in event contracts as a civil and criminal matter.

Rulemaking is moving too. The CFTC's proposed rule, Prediction Markets; Public Interest Determinations (RIN 3038-AF65), was published at 91 Fed. Reg. 35806 on June 12, 2026, with comments due July 27, 2026. It remains a proposal, not final law, and no agency has issued guidance specific to clinical-trial contracts.

The Distinction That Matters: Securities Policy Versus Event-Contract Policy

Most public biotechs have an insider trading policy. That policy almost always prohibits trading the company's stock, options and sometimes competitor securities. It is written for SEC Rule 10b-5 exposure.

A Kalshi contract on your Phase 3 readout is not a security. It is a CFTC-regulated event contract. An employee who would never buy shares ahead of topline data may not read a stock-focused policy as covering a yes/no contract on the same result. That ambiguity is the gap.

Private biotechs face a sharper version. Many have no trading policy at all because they have no public stock. Their unblinded data now has a liquid market anyway.

What Your Leadership Team Should Decide This Quarter

Policy and contracts

First, extend the insider trading policy to event contracts. Name prediction markets expressly, cover trial outcomes and FDA decisions, and include household members.

Second, push the restriction into vendor agreements. CROs, site networks, biostatistics vendors and data-monitoring committees should carry express event-contract trading prohibitions.

Controls and governance

• Map who sees unblinded or regulatory data. That list is your enforcement-risk perimeter.
• Add event contracts to annual certifications. A signed acknowledgment is cheap evidence of a compliance program.
• Brief the board. The question is whether a leak to a prediction market could invalidate trial integrity or trigger a CFTC inquiry, and who owns the response.

Ask your general counsel or outside counsel to confirm the policy language reflects CFTC, not only SEC, standards.